This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Plantago ovata seed is a plant extract indicated in the treatment of occasional constipation.
- Generic Name
- Plantago ovata seed
- DrugBank Accession Number
- DB14585
- Background
Not Available
- Type
- Biotech
- Groups
- Approved, Experimental, Investigational
- Synonyms
- Blond psyllium
- Blonde psyllium
- Indian plantain seed
- Indian psyllium
- Ispaghul
- Ispaghula
- Ispaghula extract
- Ispaghula husk
- Ispaghula seed
- Plantaginis ovatae semen
- Plantaginis ovatae testa
- Plantago brunnea seed
- Plantago fastigiata seed
- Plantago gooddingii seed
- Plantago insularis seed
- Plantago minima seed
- Psyllium seed, blonde
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetazolamide The risk or severity of dehydration can be increased when Acetazolamide is combined with Plantago ovata seed. Aclidinium The therapeutic efficacy of Plantago ovata seed can be decreased when used in combination with Aclidinium. Alfentanil The therapeutic efficacy of Plantago ovata seed can be decreased when used in combination with Alfentanil. Alloin The risk or severity of adverse effects can be increased when Plantago ovata seed is combined with Alloin. Amantadine The therapeutic efficacy of Plantago ovata seed can be decreased when used in combination with Amantadine. Amiloride The risk or severity of dehydration can be increased when Amiloride is combined with Plantago ovata seed. Amiodarone The therapeutic efficacy of Plantago ovata seed can be decreased when used in combination with Amiodarone. Amitriptyline The therapeutic efficacy of Plantago ovata seed can be decreased when used in combination with Amitriptyline. Amlodipine The therapeutic efficacy of Plantago ovata seed can be decreased when used in combination with Amlodipine. Amobarbital The therapeutic efficacy of Plantago ovata seed can be decreased when used in combination with Amobarbital. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image CONSIGEL POWDER FOR ORAL SOLUTION 3.5G Powder 3.5 G Oral XEPA-SOUL PATTINSON (MALAYSIA) SDN BHD 2021-12-02 Not applicable Malaysia 
EVAGEL POWDER FOR ORAL SOLUTION 3.5g Powder, for solution Oral APEX PHARMACY MARKETING SDN. BHD. 2020-09-08 Not applicable Malaysia FYBOGEL ORANGE Granule 3.5 g Oral บริษัท เรกคิทท์ เบนคีเซอร์ (ประเทศไทย) จำกัด 1994-12-22 Not applicable Thailand 
FYBOGEL ORANGE SACHET Powder, for solution Oral RB (HEALTH) MALAYSIA SDN BHD 2020-09-08 Not applicable Malaysia Mucilin Powder 2.45 g/5g Oral Paradigm Pharmaceuticals Inc 2018-07-30 2019-12-22 US 
MUCILIN ORANGE FLAVOUR Powder 2.45 g Oral บริษัท เบอร์ลินฟาร์มาซูติคอลอินดัสตรี้ จำกัด 2020-08-13 Not applicable Thailand MUCILIN SF Powder 3.5 g Oral บริษัท เบอร์ลินฟาร์มาซูติคอลอินดัสตรี้ จำกัด 2020-08-13 Not applicable Thailand Mucilin Sf Powder 3.5 g/5g Oral Paradigm Pharmaceuticals Inc 2018-07-30 2019-12-22 US MUCILIN SF Powder 3.5 g Oral บริษัท เบอร์ลินฟาร์มาซูติคอลอินดัสตรี้ จำกัด 2017-10-11 Not applicable Thailand MUCILIN SF MIXED BERRY FLAVOUR Powder 3500 mg Oral บริษัท เบอร์ลินฟาร์มาซูติคอลอินดัสตรี้ จำกัด 2016-02-04 Not applicable Thailand - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image อาจิโอแล็กซ์ Plantago ovata seed (52 G/100G) + Plantago seed (2.2 G/100G) + Senna leaf (0.3 G/100G) Granule บริษัท เมด้า ฟาม่าร์ (ประเทศไทย) 2016-09-26 Not applicable Thailand
Categories
- ATC Codes
- A06AC51 — Ispaghula, combinations
- Drug Categories
- Alimentary Tract and Metabolism
- Angiosperms
- Biological Products
- Bulk-Forming Laxatives
- Complex Mixtures
- Drugs for Constipation
- Embryophyta
- Eukaryota
- Gastrointestinal Agents
- Lamiales
- Laxatives
- Pharmaceutical Preparations
- Plant Extracts
- Plant Preparations
- Plantaginaceae
- Streptophyta
- Tracheophyta
- Viridiplantae
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- K9NXW456E2
- CAS number
- Not Available
References
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Terminated Treatment Syndrome, Metabolic 1 Not Available Unknown Status Treatment Fecal Incontinence 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Powder, for solution Oral Granule Oral 79.618 g Powder Oral 2.45 g/5g Powder Oral 2.45 g Powder Oral 3.5 g/5g Powder Oral 3500 mg Granule Oral 150 g Granule Oral 300 g Granule Oral 5 g Granule Oral 175 g Powder Oral 3.4 g Powder Oral 49 g Granule Oral 3.5 g Granule Powder Oral 3.5 g - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at August 19, 2018 20:47 / Updated at May 14, 2021 01:06